SHIN NIPPON BIOMEDICAL, Apr-Jun (1Q) Ordinary Profit Increases by 51%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Tue Aug 5, 2025 11:30 am JST Earnings

2395 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 【J-GAAP】

Earnings Report

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. <2395> [TSE Prime] announced its financial results at noon (11:30) on August 5th. The consolidated ordinary profit for the first quarter of the fiscal year ending March 2026 (April to June) expanded 0.51 billion yen, an increase 50.6% compared to the same period last year. Progress toward the plan for the six months ending September (first half) of 1.18 billion yen was 43.6%, exceeding the five-year average of 39.6%.

In the most recent three-month period, from April to June (1Q), the operating profit/loss margin worsened from -2.6% in the same period last year to -5.2%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	5,804	1,227	1,877	1,373	33.0	50.0	Aug 2, 2023	J-GAAP
Apr - Jun, 2024	5,549	-145	342	122	2.9	18.7	Aug 6, 2024	J-GAAP
Apr - Jun, 2025	6,477	-340	515	260	6.3	43.6	Aug 5, 2025	J-GAAP
YoY	+16.7%	-134.5%	+50.6%	+113.1%	+113.3%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	12,508	80	1,829	1,331	32.0	20	Nov 6, 2024	J-GAAP
Apr - Sep, 2025 Guidance	14,542	-97	1,180	-183	-4.4	20	May 8, 2025	J-GAAP
YoY	+16.3%	－	-35.5%	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	26,450	4,162	7,015	5,531	132.9	50	May 8, 2024	J-GAAP
Mar, 2025	32,413	2,985	6,450	4,924	118.3	50	May 8, 2025	J-GAAP
Mar, 2026 Guidance	33,272	3,550	5,927	3,550	85.3	50	May 8, 2025	J-GAAP
YoY	+2.7%	+18.9%	-8.1%	-27.9%	-27.9%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	5,549	-145	342	122	2.9	-2.6	Aug 6, 2024	J-GAAP
Jul - Sep, 2024	6,959	225	1,487	1,209	29.0	3.2	Nov 6, 2024	J-GAAP
Oct - Dec, 2024	9,727	1,813	2,309	1,874	45.0	18.6	Feb 5, 2025	J-GAAP
Jan - Mar, 2025	10,178	1,092	2,312	1,719	41.3	10.7	May 8, 2025	J-GAAP
Apr - Jun, 2025	6,477	-340	515	260	6.3	-5.2	Aug 5, 2025	J-GAAP
YoY	+16.7%	-134.5%	+50.6%	+113.1%	+113.3%